🇺🇸 FDA
Patent

US 8506959

Prevention and treatment of synucleinopathic and amyloidogenic disease

granted A61KA61K2039/505A61K38/1709

Quick answer

US patent 8506959 (Prevention and treatment of synucleinopathic and amyloidogenic disease) held by The Regents of the University of California expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Aug 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61K38/1709, A61K39/00, A61P